Sandoz Beats Amgen Bid To Delay Biosimilar Competition

Law360, New York (March 19, 2015, 7:13 PM ET) -- A California federal judge on Thursday handed Sandoz Inc. a major victory over Amgen Inc. in a high-stakes fight over the Affordable Care Act’s approval pathway for biosimilars, clearing the way for sales of the first copycat biologic approved under the law.



The ruling from U.S. District Judge Richard Seeborg applies to Sandoz’s Zarxio, a newly approved version of Amgen’s blockbuster anti-infection drug Neupogen, and concerns the information-sharing and advance-notice provisions of the ACA’s Biologics Price Competition and Innovation Act.



One part of the dispute centered...

To view the full article, register now.